Abstracts tagged "Fatigue"

Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Helena Marzo-Ortega¹, Philip Mease², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Martin Rudwaleit⁶, Maria Antonietta D'Agostino⁷, Christine de la Loge⁸, Ute Massow⁹, Vanessa Taieb¹⁰, Diana Voiniciuc¹¹ and Atul Deodhar¹², ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…
Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Kaleb Michaud¹, Shreena Kamlesh Gandhi², Sofia Pedro³, Cassandra Calabrese⁴, Patti Katz⁵ and Leonard Calabrese⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Kansas University School of Medicine - Wichita, Wichita, KS, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Cleveland Clinic Foundation, Cleveland Heights, OH, ⁵UCSF, San Rafael, CA, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…
Abstract Number: 0987 • ACR Convergence 2024
Correlates of Depression in Individuals with Chronic Fatigue Syndrome
Joan Morny¹, Raheem Robertson¹, Terrylyna Baffoe-Bonnie², Ufuoma Mamoh³, Soziema Salia⁴ and Ehizogie Edigin⁵, ¹Piedmont Athens Regional Medical Center, athens, GA, ²Medstar Health Union Memorial Hospital, Baltimore, MD, ³Medstar Union Memorial Hospital, Baltimore, MD, ⁴MedStar Union Memorial Hospital, Towson, MD, ⁵The University of Texas Health Science Center, houston, TX
Background/Purpose: Chronic fatigue syndrome (CFS) is a multifaceted illness with a wide range of symptoms. It shares similar symptomatology with depression. In situations where patients have both…
Abstract Number: 1278 • ACR Convergence 2024
The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Hunter Hogarth¹, Jida Jaffan¹, Tala El Tal², Oscar Mwizerwa¹, Asha Jeyanathan¹, Ibrahim Mohamed³, Lawrence Ng⁴, Paris Moaf⁵, Joanna Law⁵, Louise Boulard⁶, Ashley Danguecan⁷, Adrienne Davis⁸, Linda Hiraki⁴, Deborah Levy⁴ and Andrea Knight⁹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ²The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁸Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Fatigue is a prevalent and distressing symptom in childhood-onset systemic lupus erythematosus (cSLE), affecting up to 74% of patients with potential for adverse effects…
Abstract Number: 1280 • ACR Convergence 2024
Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue
Diana Valdes Cabrera¹, Tala El Tal², Santiago Arciniegas¹, Oscar Mwizerwa³, Asha Jeyanathan³, Lawrence Ng¹, Paris Moaf¹, Joanna Law⁴, Sarah Mossad⁵, Birgit Ertl-Wagner¹, Ann Yeh¹, Helen Branson¹, Adrienne Davis⁶, Linda Hiraki¹, Deborah Levy¹, Busi Zapparoli⁷, Ashley Danguecan⁸ and Andrea Knight⁹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Etobicoke, ON, Canada, ⁸The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Fatigue and brain fog are early complaints in adolescents with childhood-onset SLE (cSLE), who experience disease onset during a critical period of brain development.…
Abstract Number: 1320 • ACR Convergence 2024
Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis
Susan Murphy¹, Yen Chen², Alexandra Harper², Nirali Shah², Mary Alore², Sheri Hicks², Adam Pape³ and Dinesh Khanna², ¹University of Michigan, Plymouth, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, University of Michigan, MI
Background/Purpose: Non-pharmacological fatigue management interventions in systemic sclerosis (SSc) are limited, despite people with SSc reporting that fatigue is inadequately addressed with clinical care. We…
Abstract Number: 1520 • ACR Convergence 2024
The Influence of Trauma on Features of Type 2 SLE
Jennifer Rogers¹, Megan Clowse², David Pisetsky³, Jayanth Doss⁴, Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Rebecca Sadun⁴, Kai Sun⁴ and Amanda Eudy⁶, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University, Raleigh, NC
Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown. Since trauma has…
Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Vibeke Strand¹, Kenneth Kalunian², Ian Bruce³, Caroline Seo⁴, Kai Wai Lee⁵, Jacob Knagenhjelm⁶ and Catharina Lindholm⁶, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…
Abstract Number: 1937 • ACR Convergence 2024
Wellness and Burnout Among Pediatric Rheumatologists in North America- A 2024 CARRA Study
Kathryn Cook¹, Aviya Lanis², Arielle Hay³, Daniel Glaser⁴, Sarah Hoffmann⁵, Lakshmi Moorthy⁶, Onengiya Harry⁷, Deepika Singh⁸ and Sheetal Vora⁹, and for the CARRA Investigators, ¹Akron Children's Hospital, Akron, OH, ²Seattle Children's Hospital, Seattle, WA, ³Nicklaus Children's Hospital, Hollywood, FL, ⁴Yale University School of Medicine, New Haven, CT, ⁵Children's Hospital of Richmond at VCU, Richmond, VA, ⁶Rutgers Robert Wood Johnson Medical School, Metuchen, NJ, ⁷Brenner Children's Hospital - Wake Forest Baptist Health, Winston-Salem, NC, ⁸Valley Children's Healthcare, Clovis, CA, ⁹Atrium Health Levine Children's Hospital, Charlotte, NC
Background/Purpose: A high proportion of pediatricians experience burnout symptom impacting patient care and academic productivity. Burnout is a state of physical, emotional or mental exhaustion…
Abstract Number: 2002 • ACR Convergence 2024
Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Laura Cappelli¹, Cyd Eaton¹, Yunzhi Wang¹, Michelle Jones² and Clifton Bingham³, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins School of Medicine, Pittsburgh, PA, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an impactful and often persistent side effect of cancer immunotherapy that can lead to permanent joint damage…
Abstract Number: 2029 • ACR Convergence 2024
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort
Ilenia Di Cola¹, Lea Savey², Marion Delplanque³, Rim bourguiba³, Alessandra Bartoli⁴, Zohra Aknouche³, Fatima Bensalek³, Isabelle Kone Paut⁵, Linda Rossi Semerano⁵, Isabelle Melki⁶, Brigitte Bader-Meunier⁷, Bénédicte Neven⁶, PIERRE QUARTIER⁸, Guilaine Boursier⁹, Irina Giurgea¹⁰, Laurence Cuisset¹¹, Gilles Grateau³, Veronique Hentgen¹² and Sophie Georgin-lavialle¹³, ¹University of L'Aquila, L'Aquila, Italy, ²Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, france, France, ³Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, Paris, France, ⁴Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, italy, Italy, ⁵Kremlin Bicêtre hospital, Le Kremlin Bicêtre, France, ⁶Necker Hospital, Paris, France, ⁷Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁸Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, ⁹University of Montpellier, Montpellier, ¹⁰Trousseau hospital, Paris, France, ¹¹Cochin hospital, Paris, France, ¹²Laboratoire de Génétique des Maladies Rares et Autoinflammatoires, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CEREMAIA, CHU de Montpellier, Univ Montpellier, Montpellier, France, Le Chesnay, France, ¹³Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease worldwide. Fatigue is known to trigger FMF attacks. So far, no association has…
Abstract Number: 2225 • ACR Convergence 2024
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Maria Rodriguez-Laguna¹, Leticia Leon², Dalifer Freites Nuñez³, Cristina Hormigos-martin⁴, jose otazu Moudelle⁴, Alfredo Madrid García⁵, Benjamin fernandez-Gutierrez² and lydia Abasolo Alcazar⁶, ¹Resident in Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁴Hospital Clínico San Carlos, madrid, Spain, ⁵Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IDISCC), Madrid, Madrid, Spain, ⁶IdISSC. HCSC, Madrid, Spain
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) who remains symptomatic after failing to multiple therapies are deemed to have "difficult-to-treat" (D2T RA). Fatigue…
Abstract Number: 0357 • ACR Convergence 2024
Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
Clifton Bingham¹, Emily Molina², Amy Praestgaard³, Stefano Fiore³ and David Cella⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins, Baltimore, MD, ³Sanofi, Bridgewater, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with…
Abstract Number: 2368 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Philip Mease¹, William Tillett², Maarten de Wit³, Laure Gossec⁴, M. Elaine Husni⁵, Fabian Proft⁶, Barbara Ink⁷, Rajan Bajracharya⁷, Jason Coarse⁸, Jérémy Lambert⁹, Laura Coates¹⁰ and Alice Gottlieb¹¹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁴Sorbonne Université, Paris, France, ⁵Cleveland Clinic, Cleveland, OH, ⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Morrisville, NC, ⁹UCB Pharma, Colombes, France, ¹⁰University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: PsA significantly impacts patients' quality of life due to functional limitations, pain, and fatigue.1 Sustained relief from pain and fatigue are therefore important aims…
Abstract Number: 0358 • ACR Convergence 2024
Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
Rosa Maria Morlà Novell¹, Beatriz Frade-Sosa², Lola Tobalina Maestre³, Meritxell Sallés Lizarzaburu⁴, Virginia Ruiz-Esquide², Maria López Lasanta⁵, Georgina Salvador Alarcón⁶, Noemí Busquets Pérez⁷, Marta Valls Roc⁸, Enrique Gonzalez Dávila⁹, Jose Alfredo Gomez-Puerta¹⁰ and Raimon Sanmartí Sala¹⁰, and ARCat study Group, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³Fundació Clinic per la Recerca clínica, Barcelona, Spain, ⁴Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ⁵Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ⁶Hospital Mútua de Terrassa, Terrassa, Spain, ⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁸Hospital Universitari Josep Trueta, Girona, ⁹Universidad de La Laguna, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Fatigue is a frequent and annoying symptom in rheumatoid arthritis (RA) patients that is often not assessed at routine follow-up visits. Residual’ fatigue has…

1
2
3
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.